Skip Navigation

Mary-Ellen Taplin, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Chair, Executive Committee for Clinical Research
  • Director of Clinical Research, Lank Center for Genitourinary Oncology
  • Institute Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Bladder cancer
  • Clinical trials
  • Hormone and chemotherapy
  • Kidney cancer
  • Prostate cancer
  • Testis cancer

Diseases Treated

Contact Information

  • Appointments877-332-4294 (new)
    617-582-9725 (follow-up)
  • Office Phone Number617-582-7221
  • Fax617-632-2165

Bio

Dr. Taplin received her MD in 1986 from the University of Massachusetts, Worcester. She completed a residency in internal medicine and chief residency at the University of Massachusetts Medical Center and an oncology-hematology fellowship at Beth Israel Hospital and Harvard Medical School.

Dr. Taplin was on staff in medical oncology-hematology as an assistant and then associate professor of medicine at the University of Massachusetts from 1993 to 2003, when she joined Dana-Farber Cancer Institute.

Board Certification:

  • Hematology, 1996
  • Internal Medicine, 1989
  • Medical Oncology, 1993

Fellowship:

  • Beth Israel Deaconess Medical Center, Hematology/Oncology

Residency:

  • University of Massachusetts Medical Center, Chief Medical Resident
  • University of Massachusetts Medical Center, Internal Medicine

Medical School:

  • University of Massachusetts Medical School

Recent Awards:

  • Dana-Farber Cancer Center Medical Oncology Teaching Award 2009

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1232C
Boston MA, 02215
Get Directions

Research

Since completing her Hematology-Oncology fellowship at Beth Israel Medical Center/Harvard Medical School in 1993, Dr. Mary-Ellen Taplin has dedicated herself to academic genitourinary (GU) oncology at the University of Massachusetts Medical Center (1993-2003) and Dana-Farber Cancer Institute (DFCI)/Harvard Medical School (2003-present). Dr. Taplin has assiduously focused on clinical and correlative investigations in prostate cancer while providing outstanding patient care, teaching and mentoring trainees and developing excellent administrative skills in clinical research management. She is a key opinion leader in GU oncology and has provided leadership in all phases of clinical trials. She was the principal investigator for the first biomarker (androgen receptor spice variant) directed trial (galeterone) in metastatic prostate cancer. Leadership on the phase 3 galeterone trial and her work with abiraterone and enzalutamide demonstrates the full circle of bench to bedside, as Dr. Taplin was the first to report androgen receptor mutations in metastatic prostate cancer samples in the New England Journal of Medicine in 1995. Her work has increased the understanding of mechanisms of prostate cancer response and resistance and remains important especially in the context of next generation hormone therapy in prostate cancer. Dr. Taplin’s dedication, clinical expertise and service together with her innovation and publication record supported her promotion to Professor of Medicine at Harvard Medical School in 2017.


 

Paller CJ, Zhou XC, Heath EI, Taplin ME, Mayer T, Stein MN, Bubley GJ, Pili R, Hudson T, Kakarla R, Abbas MM, Anders NM, Dowling D, King S, Bruns AB, Wagner WD, Drake CG, Antonarakis ES, Eisenberger MA, Denmeade SR, Rudek MA, Rosner GL, Carducci MA. Muscadine Grape Skin Extract in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial. Clin Cancer Res. 2017 Nov 07.
View in: PubMed

Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, Stewart C, Rosenberg M, Francis JM, Zhang CZ, Cohen O, Oh C, Ding H, Polak P, Lloyd M, Mahmud S, Helvie K, Merrill MS, Santiago RA, O'Connor EP, Jeong SH, Leeson R, Barry RM, Kramkowski JF, Zhang Z, Polacek L, Lohr JG, Schleicher M, Lipscomb E, Saltzman A, Oliver NM, Marini L, Waks AG, Harshman LC, Tolaney SM, Van Allen EM, Winer EP, Lin NU, Nakabayashi M, Taplin ME, Johannessen CM, Garraway LA, Golub TR, Boehm JS, Wagle N, Getz G, Love JC, Meyerson M. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017 Nov 06; 8(1):1324.
View in: PubMed

Gagliano-Jucá T, Travison TG, Nguyen PL, Kantoff PW, Taplin ME, Kibel AS, Manley R, Hally K, Bearup R, Beleva YM, Huang G, Edwards RR, Basaria S. Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. J Pain Symptom Manage. 2017 Sep 21.
View in: PubMed

Calagua C, Russo J, Sun Y, Schaefer R, Lis R, Zhang Z, Mahoney K, Bubley GJ, Loda M, Taplin ME, Balk SP, Ye H. Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Clin Cancer Res. 2017 Nov 15; 23(22):6812-6822.
View in: PubMed

Beltran H, Wyatt AW, Chedgy EC, Donoghue A, Annala M, Warner EW, Beja K, Sigouros M, Mo F, Fazli L, Collins CC, Eastham J, Morris M, Taplin ME, Sboner A, Halabi S, Gleave ME. Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clin Cancer Res. 2017 Nov 15; 23(22):6802-6811.
View in: PubMed

Harshman LC, Werner L, Tripathi A, Wang X, Maughan BL, Antonarakis ES, Nakabayashi M, McKay R, Pomerantz M, Mucci LA, Taplin ME, Sweeney CJ, Lee GM, Kantoff PW. The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May; 77(13):1303-1311.
View in: PubMed

Taplin ME, Armstrong AJ, Lin P, Krivoshik A, Parli T, Tombal B, Beer TM. Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo. J Urol. 2017 Dec; 198(6):1324-1332.
View in: PubMed

Zang T, Taplin ME, Tamae D, Xie W, Mesaros C, Zhang Z, Bubley G, Montgomery B, Balk SP, Mostaghel EA, Blair IA, Penning TM. Testicular vs adrenal sources of hydroxy-androgens in prostate cancer. Endocr Relat Cancer. 2017 Aug; 24(8):393-404.
View in: PubMed

Virgo KS, Basch E, Loblaw DA, Oliver TK, Rumble RB, Carducci MA, Nordquist L, Taplin ME, Winquist E, Singer EA. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol. 2017 Jun 10; 35(17):1952-1964.
View in: PubMed

Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck BT, Sharifi N, Wright JL, Gulati R, True LD, Loda M, Matsumoto AM, Tamae D, Penning TN, Balk SP, Kantoff PW, Nelson PS, Taplin ME, Montgomery RB. Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. Clin Cancer Res. 2017 Aug 15; 23(16):4592-4601.
View in: PubMed

Li J, Alyamani M, Zhang A, Chang KH, Berk M, Li Z, Zhu Z, Petro M, Magi-Galluzzi C, Taplin ME, Garcia JA, Courtney K, Klein EA, Sharifi N. Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. Elife. 2017 Feb 13; 6.
View in: PubMed

Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin DW, Sanda M, Novotny W, Wu K, Kantoff PW, Marck BT, Plymate S, Balk SP, Nelson PS, Matsumoto AM, Lis RT, Kibel A, Haas GP, Krivoshik A, Hannah A, Taplin ME. Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res. 2017 May 01; 23(9):2169-2176.
View in: PubMed

Francini E, Taplin ME. Prostate cancer: Developing novel approaches to castration-sensitive disease. Cancer. 2017 Jan 01; 123(1):29-42.
View in: PubMed

McKay RR, Werner L, Fiorillo M, Roberts J, Heath EI, Bubley GJ, Montgomery RB, Taplin ME. Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Aug; 15(4):463-471.
View in: PubMed

McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z, Marck BT, Matsumoto AM, Domachevsky L, Zukotynski KA, Bhasin M, Bubley GJ, Montgomery B, Kantoff PW, Balk SP, Taplin ME. A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2017 Feb 15; 23(4):935-945.
View in: PubMed

McKay RR, Jacobus S, Fiorillo M, Ledet EM, Cotogna PM, Steinberger AE, Jacene HA, Sartor O, Taplin ME. Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. Clin Genitourin Cancer. 2017 Apr; 15(2):e289-e298.
View in: PubMed

McKay RR, Werner L, Fiorillo M, Nakabayashi M, Kantoff PW, Taplin ME. Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2016 Dec; 19(4):398-405.
View in: PubMed

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016 Aug 04; 375(5):443-53.
View in: PubMed

Bellmunt J, Zhou CW, Mullane SA, Werner L, Taplin ME, Fay AP, Choueiri TK, Orsola A, Takeda DY, Hahn WC, Kim J, Sonpavde G, Bowden M. Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Br J Cancer. 2016 Jun 28; 115(1):12-9.
View in: PubMed

Li Z, Alyamani M, Li J, Rogacki K, Abazeed M, Upadhyay SK, Balk SP, Taplin ME, Auchus RJ, Sharifi N. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature. 2016 05 26; 533(7604):547-51.
View in: PubMed

McKay RR, Zurita AJ, Werner L, Bruce JY, Carducci MA, Stein MN, Heath EI, Hussain A, Tran HT, Sweeney CJ, Ross RW, Kantoff PW, Slovin SF, Taplin ME. A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. J Clin Oncol. 2016 Jun 01; 34(16):1913-20.
View in: PubMed

Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel EA, Nelson PS, Taplin ME, Balk SP, Cai C. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clin Cancer Res. 2016 Jul 15; 22(14):3672-82.
View in: PubMed

Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20; 34(12):1402-18.
View in: PubMed

Muralidhar V, Regan MM, Werner L, Nakabayashi M, Evan CP, Bellmunt J, Choueiri TK, Elfiky AA, Harshman LC, McKay RR, Pomerantz MM, Sweeney CJ, Taplin ME, Kantoff PW, Nguyen PL. Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 Aug; 14(4):e299-305.
View in: PubMed

Kryukov GV, Bielski CM, Samocha K, Fromer M, Seepo S, Gentry C, Neale B, Garraway LA, Sweeney CJ, Taplin ME, Van Allen EM. Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors. Clin Cancer Res. 2016 May 01; 22(9):2183-9.
View in: PubMed

Montgomery B, Eisenberger MA, Rettig MB, Chu F, Pili R, Stephenson JJ, Vogelzang NJ, Koletsky AJ, Nordquist LT, Edenfield WJ, Mamlouk K, Ferrante KJ, Taplin ME. Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer. Clin Cancer Res. 2016 Mar 15; 22(6):1356-63.
View in: PubMed

Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard S. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. Eur Urol. 2016 May; 69(5):924-32.
View in: PubMed

Kim HL, Halabi S, Li P, Mayhew G, Simko J, Nixon AB, Small EJ, Rini B, Morris MJ, Taplin ME, George D. A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). EBioMedicine. 2015 Nov; 2(11):1814-20.
View in: PubMed

Taplin ME, Balk SP. Has the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer? JAMA Oncol. 2015 Aug; 1(5):577-9.
View in: PubMed

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Sboner A, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM. Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 2015 Jul 16; 162(2):454.
View in: PubMed

Kehr E, Masry P, Lis R, Loda M, Taplin ME, Hirsch MS. Detecting metastatic prostate carcinoma in pelvic lymph nodes following neoadjuvant hormone therapy: the eyes have it! Histopathology. 2016 Jan; 68(2):303-7.
View in: PubMed

Bellmunt J, Werner L, Leow JJ, Mullane SA, Fay AP, Riester M, Van Hummelen P, Taplin ME, Choueiri TK, Van Allen E, Rosenberg J. Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. PLoS One. 2015; 10(6):e0124711.
View in: PubMed

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM. Integrative clinical genomics of advanced prostate cancer. Cell. 2015 May 21; 161(5):1215-1228.
View in: PubMed

McKay RR, Gray KP, Hayes JH, Bubley GJ, Rosenberg JE, Hussain A, Kantoff PW, Taplin ME. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. Cancer. 2015 Aug 01; 121(15):2603-11.
View in: PubMed

Higano CS, Beer TM, Taplin ME, Efstathiou E, Hirmand M, Forer D, Scher HI. Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. Eur Urol. 2015 Nov; 68(5):795-801.
View in: PubMed

Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin ME, Taub JM, Herman B, Higano CS, Doot RK, Hartfeil D, Febbo PG, Mankoff DA. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687. J Nucl Med. 2015 Mar; 56(3):354-60.
View in: PubMed

Bellmunt J, Mullane SA, Werner L, Fay AP, Callea M, Leow JJ, Taplin ME, Choueiri TK, Hodi FS, Freeman GJ, Signoretti S. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015 Apr; 26(4):812-7.
View in: PubMed

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb; 16(2):152-60.
View in: PubMed

McKay RR, Mamlouk K, Montgomery B, Taplin ME. Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report. Clin Genitourin Cancer. 2015 Aug; 13(4):e325-8.
View in: PubMed

Zukotynski KA, Kim CK, Gerbaudo VH, Hainer J, Taplin ME, Kantoff P, den Abbeele AD, Seltzer S, Sweeney CJ. (18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. Am J Nucl Med Mol Imaging. 2015; 5(1):72-82.
View in: PubMed

Tamae D, Mostaghel E, Montgomery B, Nelson PS, Balk SP, Kantoff PW, Taplin ME, Penning TM. The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. Chem Biol Interact. 2015 Jun 05; 234:332-8.
View in: PubMed

Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clin Genitourin Cancer. 2015 Jun; 13(3):e191-8.
View in: PubMed

Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2015 Apr; 13(2):113-23.
View in: PubMed

Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin ME. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015 Mar 15; 21(6):1273-80.
View in: PubMed

Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014 Nov 20; 32(33):3705-15.
View in: PubMed

Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, Garrels K, Hotte S, Kattan MW, Raghavan D, Saad F, Taplin ME, Walker-Dilks C, Williams J, Winquist E, Bennett CL, Wootton T, Rumble RB, Dusetzina SB, Virgo KS. Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014 Oct 20; 32(30):3436-48.
View in: PubMed

McKay RR, Zukotynski KA, Werner L, Voznesensky O, Wu JS, Smith SE, Jiang Z, Melnick K, Yuan X, Kantoff PW, Montgomery B, Balk SP, Taplin ME. Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):325-31.
View in: PubMed

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Jul 31; 371(5):424-33.
View in: PubMed

Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20; 32(18):1889-94.
View in: PubMed

Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis JM, Zhang CZ, Shalek AK, Satija R, Trombetta JJ, Lu D, Tallapragada N, Tahirova N, Kim S, Blumenstiel B, Sougnez C, Lowe A, Wong B, Auclair D, Van Allen EM, Nakabayashi M, Lis RT, Lee GS, Li T, Chabot MS, Ly A, Taplin ME, Clancy TE, Loda M, Regev A, Meyerson M, Hahn WC, Kantoff PW, Golub TR, Getz G, Boehm JS, Love JC. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014 May; 32(5):479-84.
View in: PubMed

Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014 May; 4(5):546-53.
View in: PubMed

Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov; 66(5):815-25.
View in: PubMed

Yao X, Choudhury AD, Yamanaka YJ, Adalsteinsson VA, Gierahn TM, Williamson CA, Lamb CR, Taplin ME, Nakabayashi M, Chabot MS, Li T, Lee GS, Boehm JS, Kantoff PW, Hahn WC, Wittrup KD, Love JC. Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. Integr Biol (Camb). 2014 Apr; 6(4):388-98.
View in: PubMed

Nadal R, Taplin ME, Bellmunt J. Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial. Future Oncol. 2014 Feb; 10(3):351-62.
View in: PubMed

Fennessy FM, McKay RR, Beard CJ, Taplin ME, Tempany CM. Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls. Transl Oncol. 2014 Feb; 7(1):120-9.
View in: PubMed

Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B. Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol. 2014 Jan 20; 32(3):229-37.
View in: PubMed

Taplin ME, Berry WR, Casey AM, Aslo A. A urologic oncology roundtable discussion: issues to consider in choosing treatment for metastatic castration-resistant prostate cancer. Hosp Pract (1995). 2013 Oct-Nov; 41(4):81-2.
View in: PubMed

McKay RR, Taplin ME, Choueiri TK. Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer. Hematol Oncol Clin North Am. 2013 Dec; 27(6):1261-83, ix.
View in: PubMed

McKay RR, Choueiri TK, Taplin ME. Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. Drugs. 2013 Sep; 73(13):1417-30.
View in: PubMed

Harshman LC, Taplin ME. Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer. Adv Ther. 2013 Aug; 30(8):727-47.
View in: PubMed

Tamae D, Byrns M, Marck B, Mostaghel EA, Nelson PS, Lange P, Lin D, Taplin ME, Balk S, Ellis W, True L, Vessella R, Montgomery B, Blair IA, Penning TM. Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum. J Steroid Biochem Mol Biol. 2013 Nov; 138:281-9.
View in: PubMed

Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW. Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer. 2013 Aug 15; 119(16):2990-8.
View in: PubMed

Taplin ME. Secondary hormone therapy for castration-resistant prostate cancer. Oncology (Williston Park). 2013 May; 27(5):371-2.
View in: PubMed

Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh W, Morganstern DE, Kantoff PW, Taplin ME. Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology. 2013 Mar; 81(3):611-6.
View in: PubMed

Scher HI, Fizazi K, Taplin ME, Forer D, Hirmand M, De Bono JS. Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes. J Clin Oncol. 2013 Feb 20; 31(6_suppl):20.
View in: PubMed

Fizazi K, Saad F, Chi KN, Taplin ME, Sternberg CN, Armstrong AJ, Hirmand M, Forer D, De Bono JS. Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor. J Clin Oncol. 2013 Feb 20; 31(6_suppl):6.
View in: PubMed

Jacobus SJ, Qu AQ, Sweeney C, Appleman LJ, Tretter CP, Bubley GJ, Elfiky A, Park R, Stack EC, Signoretti S, Walsh MK, Steele G, Hirsch MS, Krajewski KM, Taplin ME, Rosenberg JE, Ross RW. A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates. J Clin Oncol. 2013 Feb 20; 31(6_suppl):278.
View in: PubMed

Xie W, Nakabayashi M, Ross RW, Fennessy FM, Tempany CM, Choueiri TK, Khine K, Kantoff PW, Taplin ME, Oh WK. Paradoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):23.
View in: PubMed

Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48.
View in: PubMed

Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012 Dec; 110(11):1729-35.
View in: PubMed

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27; 367(13):1187-97.
View in: PubMed

Vinjamoori AH, Jagannathan JP, Shinagare AB, Taplin ME, Oh WK, Van den Abbeele AD, Ramaiya NH. Atypical metastases from prostate cancer: 10-year experience at a single institution. AJR Am J Roentgenol. 2012 Aug; 199(2):367-72.
View in: PubMed

Courtney KD, Taplin ME. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer. Curr Opin Oncol. 2012 May; 24(3):272-7.
View in: PubMed

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, De Wit R, Mulders P, Hirmand M, Selby B, De Bono JS. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. J Clin Oncol. 2012 Feb 10; 30(5_suppl):LBA1.
View in: PubMed

Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer. 2012 Oct 01; 118(19):4777-84.
View in: PubMed

Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn DI, Hahn NM, Hutson TE, Sonpavde G, Morrissey SC, Buckle GC, Kim WY, Petrylak DP, Ryan CW, Eisenberger MA, Mortazavi A, Bubley GJ, Taplin ME, Rosenberg JE, Kantoff PW. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012 Feb 10; 30(5):507-12.
View in: PubMed

Nakabayashi M, Werner L, Oh WK, Regan MM, Kantoff PW, Taplin ME. Secondary hormonal therapy in men with castration-resistant prostate cancer. Clin Genitourin Cancer. 2011 Dec; 9(2):95-103.
View in: PubMed

Guancial EA, Taplin ME. Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatment. Clin Genitourin Cancer. 2011 Dec; 9(2):130-2.
View in: PubMed

Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15; 17(14):4854-61.
View in: PubMed

Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, Oh WK, Lee GS, Kantoff PW. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011 Jun 20; 29(18):2565-73.
View in: PubMed

Oh WK, Galsky MD, Barry M, Fennessey F, Richie JP, Hayes JH, Bhatt RS, Taplin M, Febbo PG, Ross RW. A phase II study of neoadjuvant docetaxel (D) plus bevacizumab (B) in patients (pts) with high-risk localized prostate cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):4642.
View in: PubMed

Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh WV, Morganstern D, Kantoff PW, Regan MM, Taplin M. Follow-up study of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):4657.
View in: PubMed

Wu Y, Rosenberg JE, Taplin ME. Novel agents and new therapeutics in castration-resistant prostate cancer. Curr Opin Oncol. 2011 May; 23(3):290-6.
View in: PubMed

Shinagare AB, Fennessy FM, Ramaiya NH, Jagannathan JP, Taplin ME, Van den Abbeele AD. Urothelial cancers of the upper urinary tract: metastatic pattern and its correlation with tumor histopathology and location. J Comput Assist Tomogr. 2011 Mar-Apr; 35(2):217-22.
View in: PubMed

Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD. Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol. 2011 Jan; 196(1):117-22.
View in: PubMed

Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010 Apr 24; 375(9724):1437-46.
View in: PubMed

Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 20; 28(9):1496-501.
View in: PubMed

Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15; 15(22):7099-105.
View in: PubMed

Nakabayashi M, Oh WK, Jacobus S, Regan MM, Taplin ME, Kantoff PW, Rosenberg JE. Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. BJU Int. 2010 May; 105(10):1392-6.
View in: PubMed

Sartor O, Nakabayashi M, Taplin ME, Ross RW, Kantoff PW, Balk SP, Oh WK. Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. Clin Genitourin Cancer. 2009 Oct; 7(3):E90-2.
View in: PubMed

Ryan C, Efstathiou E, Smith M, Taplin M, Bubley G, Logothetis C, Kheoh T, Haqq C, Molina A, Small EJ. Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol. 2009 May 20; 27(15_suppl):5046.
View in: PubMed

Danila DC, de Bono J, Ryan CJ, Denmeade S, Smith M, Taplin M, Bubley G, Molina A, Haqq C, Scher HI. Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto). J Clin Oncol. 2009 May 20; 27(15_suppl):5048.
View in: PubMed

Scher HI, Beer TM, Higano CS, Taplin M, Efstathiou E, Anand A, Hung D, Hirmand M, Fleisher M. Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). J Clin Oncol. 2009 May 20; 27(15_suppl):5011.
View in: PubMed

Oh WK, Febbo PG, Richie JP, Fennessy FM, Scibelli G, Hayes JH, Choueiri TK, Tempany CM, Taplin ME, Ross RW. A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. J Clin Oncol. 2009 May 20; 27(15_suppl):5060.
View in: PubMed

Choueiri TK, Xie W, D'Amico AV, Ross RW, Hu JC, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009 Mar 01; 115(5):981-7.
View in: PubMed

Taplin ME. Androgen receptor: role and novel therapeutic prospects in prostate cancer. Expert Rev Anticancer Ther. 2008 Sep; 8(9):1495-508.
View in: PubMed

Ryan C, Smith MR, Rosenberg JE, Lin AM, Taplin M, Kantoff PW, Huey V, Kim J, Small EJ. Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer (CRPC). J Clin Oncol. 2008 May 20; 26(15_suppl):5018.
View in: PubMed

Ross RW, Manola J, Oh WK, Ryan C, Kim J, Rastarhuyeva I, Yap JT, Van Den Abbeele AD, Kantoff PW, Taplin M. Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. J Clin Oncol. 2008 May 20; 26(15_suppl):5069.
View in: PubMed

Taplin M, Ko Y, Regan MM, Beer TM, Carducci MA, Mathew P, Bubley G, Oh WK, Kantoff PW, Balk SP. Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC). J Clin Oncol. 2008 May 20; 26(15_suppl):5068.
View in: PubMed

Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int. 2008 May; 101(9):1084-9.
View in: PubMed

Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP. A Phase II Study of Mifepristone (RU-486) in Castration Resistant Prostate Cancer with Correlative Assessment of Androgen related hormones. BJU. 2008; 101:1084-89.
View in: PubMed

Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008 Mar 15; 112(6):1247-53.
View in: PubMed

Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008 Feb 20; 26(6):842-7.
View in: PubMed

Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int. 2008 Feb; 101(3):308-12.
View in: PubMed

Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008 Feb 01; 112(3):521-6.
View in: PubMed

D'Amico AV, Halabi S, Tempany C, Titelbaum D, Loffredo M, McMahon E, Taplin ME, Sanford B, Small EJ. Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant hormonal therapy for higher-risk prostate cancer and recurrence in men managed using radiation therapy: Results of CALGB 9682. Int J Radiat Oncol Biol Phys . 2008.
View in: PubMed

C. Ryan, M. R. Smith, J. E. Rosenberg, A. M. Lin, M. Taplin, P. W. Kantoff, V. Huey, J. Kim, E. J. Small. Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer (CRPC). J Clin Oncol. 2008; 26(May 20):abstr 5018.
View in: PubMed

Taplin ME, Regan M, Koo Y, Beer T, Carducci M, Bubley G, Oh W, Kantoff P, Balk SP. Phase II trial of ketoconazole, hydrocortisone and dutastride (KHAD) for castration resistant prostate cancer (CRPC) with correlative assessment of adrenal androgen levels. Proc Am Soc Clin Onc. 2008; 26(2008):abst 5062.
View in: PubMed

Ross R, Manola J, OH W, Beer T, Kim J, Rastarhuyeva I, Kantoff P, Taplin ME. Phase I trial of RAD001 (R) and docetaxeol (D) in castration resistant prostate cancer (CRPC) with PET assessment of RAD001 activity. Proc Am Soc Clin Onc. 2008; 26(May 20):abstr 5069.
View in: PubMed

M. Taplin, Y. Ko, M. M. Regan, T. M. Beer, M. A. Carducci, P. Mathew, G. Bubley, W. K. Oh, P. W. Kantoff, S. P. Balk. Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC). J Clin Oncol. 2008; 26(May 20):abstr 5068.
View in: PubMed

R. W. Ross, J. Manola, W. K. Oh, C. Ryan, J. Kim, I. Rastarhuyeva, J. T. Yap, A. D. Van Den Abbeele, P. W. Kantoff, M. Taplin. Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. J Clin Oncol. 2008; 26(May 20):abstr 5069.
View in: PubMed

Guise TA, McLeod D, Lawton C, Sieber P, Taplin ME. Osteporosis and Bone Fracture: Evaluation. 2007.
View in: PubMed

Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Kantoff PW, Beard C, Oh WK . Phase II study of low dose and high dose premarin in androgen independent prostate cancer. J Urol. 2007; 177(6):2146-50.
View in: PubMed

Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol. 2007 Jun; 177(6):2146-50.
View in: PubMed

D. Andrew Loblaw, Katherine S. Virgo, Robert Nam, Mark Somerfield, Edgar Ben-Josef, David S. Mendelson, Richard Middleton, Stewart A. Sharp, Thomas J. Smith, James Talcott, Mary Ellen Taplin, Nicholas J. Vogelzang, James L. Wade, III, Charles L. Bennett, and Howard I. Scher . Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer --2006 Update of an American Society of Clinical Oncology Practice Guideline . J Clin Oncol. 2007; 25(12):1596-605.
View in: PubMed

Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL, Bennett CL, Scher HI. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20; 25(12):1596-605.
View in: PubMed

Taplin ME. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol. 2007 Apr; 4(4):236-44.
View in: PubMed

Oh WK. , Jacobus S., Ross RW, Inman M., Taplin ME., Ryan C, Eilers K., Beer T. A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy. Proc Am Soc Clin Onc. 2007.
View in: PubMed

Sartor A. O., Nakabayashi M., Taplin ME., Ross R., Kantoff PK., Balk S., Oh W. K. Activity of dustasteride plus ketoconazole in hormone-refractory prostate cancer (HRPC) after progression on ketoconzole alone. Proc Am Soc Clin Onc. 2007.
View in: PubMed

Taplin ME. Case report and review: a patient with rising PSA after radical prostatectomy treated with docetaxel, estramustine, and 15 months of androgen deprivation - 7-Year Remission. Am J Hematol Oncol. 2007; 6(4 ):1-3.
View in: PubMed

Schwarzberg A. B., Kantoff P. W., Michaelson M. D., Oh W. K., Taplin ME., Wood B.C., Smith M.R. Phase II study of trilostane and hydrocortisone for androgen-independent prostate cancer. Proc Am Soc Clin Onc. 2007.
View in: PubMed

Taplin ME, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol. 2006 Dec 01; 24(34):5408-13.
View in: PubMed

Taplin M, Xie W, Morganstern D, Bubley G, Ernstoff M, Regan M. Chemo-hormonal therapy for biochemical progression of prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4559.
View in: PubMed

Berry DL, Moinpour CM, Jiang CS, Ankerst DP, Petrylak DP, Vinson LV, Lara PN, Jones S, Taplin ME, Burch PA, Hussain MH, Crawford ED. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol. 2006 Jun 20; 24(18):2828-35.
View in: PubMed

Hayes JH, Oh WK, Kantoff PW, Manola JB, Smith MR, Gelmann EP, Bubley G, Balk SP, Taplin M. Mifepristone (RU-486) in androgen independent prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):14508.
View in: PubMed

Pomerantz M, Manola J, Taplin M, Bubley G, Inman M, Lowell J, Kantoff P, Oh WK. Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC). J Clin Oncol. 2006 Jun 20; 24(18_suppl):4560.
View in: PubMed

Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr 19; 98(8):516-21.
View in: PubMed

In: Love N, ed. Faculty: Dicker AP, Klein EA, McLeod DG, Taplin ME. Prostate Cancer Update: Conversations with urologic oncology leaders bridging the gap between research and patient care. 2006.
View in: PubMed

Ross RW, Halabi S, Ou SS, Rajeshkumar BR, Woda BA, Vogelzang NJ, Small EJ, Taplin ME, Kantoff PW. Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study. Clin Cancer Res. 2005 Nov 15; 11(22):8109-13.
View in: PubMed

Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, Oh WK. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int. 2005 Oct; 96(6):783-6.
View in: PubMed

Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology. 2005 Aug; 66(2):386-91.
View in: PubMed

Michaelson MD, Gilligan T, Oh W, Kantoff P, Taplin ME, Izquierdo MA, Flores L, Smith MR. Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). J Clin Oncol. 2005 Jun; 23(16_suppl):4517.
View in: PubMed

Michaelson MD, Gilligan T, Oh W, Kantoff P, Taplin M, Izquierdo M, Flores L, Smith MR. . Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). (abstract). Proc Am Soc Clin Onc. 2005.
View in: PubMed

Nakabayashi M, Regan MM, Lifsey D, Evan CP, Kantoff PW, Taplin ME, Sartor O, Oh WK. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer (AIPC). (abstract). Proc Am Soc Clin Onc. 2005.
View in: PubMed

Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 07; 351(15):1513-20.
View in: PubMed

Berry DL, Moinpour CM, Jiang C, Vinson LV, Lara PN, Lanier S, Taplin ME, Burch PA, Petrylak DP, Crawford ED. Quality of life (QOL) and pain in advanced stage prostate cancer: impact of missing data on evaluating palliation in SWOG 9916. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4579.
View in: PubMed

Taplin ME, George DJ, Halabi S, Sellers WR, Sanford B, Hennessy KT, Mihos CG, Small EJ, Kantoff PW. Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4557.
View in: PubMed

Tay MH, George DJ, Gilligan TD, Kelly SM, Appleby L, Taplin ME, Febbo PG, Kantoff PW, Oh WK. Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4679.
View in: PubMed

Crawford ED, Pauler DK, Tangen CM, Hussain MH, Small EJ, Taplin ME, Burch PA, Greene GF, Lara P, Petrylak DP. Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4505.
View in: PubMed

Mobley JA, Lam YW, Lau KM, Pais VM, L'Esperance JO, Steadman B, Fuster LM, Blute RD, Taplin ME, Ho SM. Monitoring the serological proteome: the latest modality in prostate cancer detection. J Urol. 2004 Jul; 172(1):331-7.
View in: PubMed

Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, Middleton R, Porterfield H, Sharp SA, Smith TJ, Taplin ME, Vogelzang NJ, Wade JL, Bennett CL, Scher HI. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004 Jul 15; 22(14):2927-41.
View in: PubMed

Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem. 2004 Feb 15; 91(3):483-90.
View in: PubMed

Miller, R [Beer TM, Taplin ME, Oh W.]. Special Report: evolving role of chemotherapy in the management of prostate cancer. 2004.
View in: PubMed

Taplin ME, George DJ, Halabi S, Sellers WR, Sanford B, Hennessy KT, Mihos CG, Small EJ, Kantoff PW. . Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on cancer and leukemia group B (CALGB) 9480. Proc Am Soc Clin Onc. 2004.
View in: PubMed

Taplin ME, Kantoff PW. . Chapter 3: External Beam Radiotherapy, Radiopharmaceuticals, and Chemotherapy for Hormone-Refactory Prostate Cancer. In: Management of Skeletal Complications of Prostate Cancer and Other Genitourinary Malignancies. Kantoff PW, Saad F, Smith MR. 2004; 87-151.
View in: PubMed

Berry D. L., Moinpour C.M., Jiang C., Vinson L.V., Lara, P.N., Lanier, S., Taplin, M.E., Burch, P.A., Petrylak, D.P., Crawford E. D. Quality of life (QOL) and pain in advanced prostate cancer: impact of missing data on evaluating palliation in SWOG 9916. POSTER DISCUSSION. Proc Am Soc Clin Onc. 2004.
View in: PubMed

Chun NS, Savani B, Seder RH, Taplin ME. Acute renal failure after intravenous anti-D immune globulin in an adult with immune thrombocytopenic purpura. Am J Hematol. 2003 Dec; 74(4):276-9.
View in: PubMed

Taplin ME, Kantoff PW. The ingredients for prostate cancer nomograms: the addition of biomarkers sets the table for future recipes. J Clin Oncol. 2003 Oct 01; 21(19):3552-3.
View in: PubMed

Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 2003 Jul 15; 21(14):2673-8.
View in: PubMed

Taplin ME. Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. Rev Urol. 2003; 5 Suppl 2:S3-S13.
View in: PubMed

Taplin ME. Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. Rev Urol. 2003; 5 Suppl 3:S3-S13.
View in: PubMed

Chodak GW, Keane T, Klotz L, and the Hormone Therapy Study Group (Taplin ME). Critical evaluation of hormone therapy for carcinoma of the prostate. Urology. 2002; 60:201-208.
View in: PubMed

Taplin, ME, Morganstern DE, Ernstoff MS, Marchesani BJ, Rajeshkumar B, Bubley GJ. . Docetaxel (D), estramustine (E) and short-term androgen withdrawal for patients with a rising PSA after definitive local therapy of prostate cancer. Proc Am Soc Clin Onc. 2002.
View in: PubMed

Bubley GJ, Balk SP, Joyce RM, Taplin ME. Lack of effect of aminoglutethimide and hydrocortisone added to high-dose bicalutamide for androgen independent prostate cancer. The Prostate J. 2002; 3:1-7.
View in: PubMed

Taplin ME, Ho SM. Clinical review 134: The endocrinology of prostate cancer. J Clin Endocrinol Metab. 2001 Aug; 86(8):3467-77.
View in: PubMed

Taplin ME, Bubley GJ, Rajeshkumar B, Shuster T, Ko YJ, Morganstern DE. Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer. Semin Oncol. 2001 Aug; 28(4 Suppl 15):32-9.
View in: PubMed

Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H, Ho SM. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol. 2001 Jul; 159(1):79-92.
View in: PubMed

Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol. 2001 May 01; 19(9):2509-16.
View in: PubMed

Taplin ME, Halabi S, Rajeskumar B, Mcquain C, Woda BA, Picus J, Hayes DF, Vogelzang NJ, Small EJ. Androgen receptor mutations in androgen independent prostate cancer (AiPCa) do not correlate with the anti-androgen withdrawal response: Cancer and Leukemia Group B (CALGB) 9663. Proc Am Soc Clin Onc. 2001.
View in: PubMed

Taplin ME, Rajeskumar B, Woda B, Halabi S, Vogelzang NJ, Small E. Androgen receptor mutations in advanced prostate cancer: preliminary results of CALGB 9663. Proc Am Soc Clin Onc. 2000; 19:1297.
View in: PubMed

Small E, Taplin ME, Prins GS. Physiology and endocrinology of the prostate. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, eds. Comprehensive Textbook of Genitourinary Oncology. 2000.
View in: PubMed

Savarese D, Taplin ME, Halabi S, Hars V, Kreis W, Vogelzang N. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780. Semin Oncol. 1999 Oct; 26(5 Suppl 17):39-44.
View in: PubMed

Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 1999 Jun 01; 59(11):2511-5.
View in: PubMed

Bubley GJ, Taplin ME. Novel therapeutic strategies in prostate cancer. In: D'Amico A, Hanks G, eds. Radiotherapeutic Management of Carcinoma of the Prostate. 1999.
View in: PubMed

Savarese D, Taplin ME, Marchesani B, Kreis W, Akerley W, Godley P, Halabi S Vogelzang NJ. A Phase II Study of docetaxel, estramustine and low dose hydrocortisone in hormone refractory prostate cancer. Proc Am Soc Clin Onc. 1999; 18:295.
View in: PubMed

Savarese D, Taplin ME, Kreis W, Akerley W, Godley P, Halabi S, Marchessani B, Vogelzang NJ. A Phase II Study of docetaxel, estramustine and low dose hydrocortisone in men with hormone refractory prostate cancer: preliminary results of CALGB 9780. Proc AUA. 1999.
View in: PubMed

Becker PS, O’Donnell J, Sarcinelli F, Pechet L, Taplin ME, Walsh W, Stewart FM, Quesenberry PJ. GM-CSF Priming with successive concomitant therapy with low-dose ARA-C for older patients with advanced myelodysplastic syndrome (MDS), secondary or refractory acute myeloid leukemia (AML). Am Society of Hematology. 1998.
View in: PubMed

Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol. 1998 Jan; 159(1):149-53.
View in: PubMed

Taplin ME, Rajeshkumar B, Bubley GJ, Balk SP. Androgen receptor mutations from androgen independent prostate cancer are associated with previous hydroxyflutamide treatment. Keystone Symposium. 1998; 318.
View in: PubMed

Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res. 1997 Aug; 3(8):1383-8.
View in: PubMed

Taplin ME, Frantz ME, Canning C, Ritz J, Blumberg RS, Balk SP. Evidence against T-cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expression. Immunology. 1996 Mar; 87(3):402-7.
View in: PubMed

Fenton MA, Rode P. Constantine M, Balk SP, Gaynes L, DeWolf WC, Taplin ME, Bubley GJ. Bicalutamide for androgen-independent prostate cancer. Proc Am Soc Clin Onc. 1996; 14:262.
View in: PubMed

Balk SP, Shuster TD, Fenton MA, Taplin ME, Bubley GJ. Functional analysis of mutant androgen receptor from androgen independent prostate cancer keystone symposia: breast and prostate cancer: Basic Mechanisms. 1996.
View in: PubMed

Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995 May 25; 332(21):1393-8.
View in: PubMed

Taplin ME, Bubley GJ, Frantz M, Balk SP. Androgen receptor mutations in human hormone-independent prostate cancer. Proc Am Cancer Res. 1994; 35:273.
View in: PubMed

Taplin ME, Bubley GJ, Frantz, M, Balk SP. Androgen receptor mutations in human hormone-independent prostate cancer. J. Cellular Biochemistry. 1994; 239.
View in: PubMed

Taplin ME, Eder J, Muss H, Homesley H, Huhn R, Schnipper L, Come S. Repeated intensive cyclophosphamide, doxorubicin and VP-16 with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF). Proc Am Soc Clin Onc. 1992; 11:1414.
View in: PubMed

Taplin ME, Linden CH. Poisoning by salicylates and other nonsteroidal anti-inflammatory drugs. In: Rippe JM, Irwin RS, Alpert JS, Fink M, eds. Intensive Care Medicine. 1991.
View in: PubMed

Russo AR, Stone SL, Taplin ME, Snapper HJ, Doern GV. Presumptive evidence for Blastocystis hominis as a cause of colitis. Arch Intern Med. 1988 May; 148(5):1064.
View in: PubMed

Hitzhusen JC, Taplin ME, Stephenson WP, Ansell JE. Vitamin B12 levels and age. Am J Clin Pathol. 1986 Jan; 85(1):32-6.
View in: PubMed

Top